A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the Justice Department on Tuesday, clearing the way for the company to finalize a settlement…
BioAge bets on inflammation, a short Pfizer career, and more biotech news from The Readout
A U.S. judge is expected to direct Purdue Pharma to forfeit $225 million to the Justice Department, clearing the way for a massive settlement
To kick off KFF’s Business of Health with Chip Kahn, KFF’s Drew Altman explains how KFF is continually evolving to research, analyze and lead on health policy. Chip and Drew…
Philippe Pouletty is a physician who’s an inventor, French venture capitalist, and the founder of Carvolix. Carvolix is a medical technology company that is introducing AI into cardiology. Before Carvolix,…
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.
Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation officer.
A CAR-T trial shows promise in preventing smoldering multiple myeloma from becoming the real thing.
An authoritative look at current FDA-approved weight loss medications, their brands and results, and how obesity intersects with disability
The Breakthrough Prize winners, Trump's psychedelics executive order, and more biotech news from The Readout